Structural correlates of survival in progressive supranuclear palsy.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 01 05 2023
revised: 12 08 2023
accepted: 25 09 2023
medline: 13 11 2023
pubmed: 8 10 2023
entrez: 7 10 2023
Statut: ppublish

Résumé

Many studies of the Richardson's syndrome phenotype of progressive supranuclear palsy (PSP) have elucidated regions of progressive atrophy and neural correlates of clinical severity. However, the neural correlates of survival and how these differ according to variant phenotypes are poorly understood. We set out to identify structural changes that predict severity and survival from scanning date to death. Structural magnetic resonance imaging data from 112 deceased people with clinically defined 'probable' or 'possible' PSP were analysed. Neuroanatomical regions of interest volumes, thickness and area were correlated with 'temporal stage', defined as the ratio of time from symptom onset to death, time from scan to death ('survival from scan'), and in a subset of patients, clinical severity, adjusting for age and total intracranial volume. Forty-nine participants had post mortem confirmation of the diagnosis. Using T1-weighted magnetic resonance imaging, we confirmed the midbrain, and bilateral cortical structural correlates of contemporary disease severity. Atrophy of the striatum, cerebellum and frontotemporal cortex correlate with temporal stage and survival from scan, even after adjusting for severity. Subcortical structure-survival relationships were stronger in Richardson's syndrome than variant phenotypes. Although the duration of PSP varies widely between people, an individual's progress from disease onset to death (their temporal stage) reflects atrophy in striatal, cerebellar and frontotemporal cortical regions. Our findings suggest magnetic resonance imaging may contribute to prognostication and stratification of patients with heterogenous clinical trajectories and clarify the processes that confer mortality risk in PSP.

Identifiants

pubmed: 37804622
pii: S1353-8020(23)00945-8
doi: 10.1016/j.parkreldis.2023.105866
pmc: PMC7615224
mid: EMS188476
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105866

Subventions

Organisme : Medical Research Council
ID : MR/P01271X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 220258
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 103838
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Department of Health
ID : IS-BRC-1215-20014
Pays : United Kingdom

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest.

Auteurs

Duncan Street (D)

Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, UK.

W Richard Bevan-Jones (WR)

Department of Psychiatry, University of Cambridge, UK.

Maura Malpetti (M)

Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, UK.

P Simon Jones (PS)

Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, UK.

Luca Passamonti (L)

Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, UK; Consiglio Nazionale Delle Ricerche (CNR), Istituto di Bioimmagini e Fisiologia Molecolare (IBFM), Milano, Italy.

Boyd Cp Ghosh (BC)

Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, UK; Wessex Neurological Centre, University Hospitals Southampton NHS Foundation Trust, Southampton, UK.

Timothy Rittman (T)

Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, UK.

Ian Ts Coyle-Gilchrist (IT)

Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, UK; Norfolk and Norwich NHS Foundation Trust, Norwich, UK.

Kieren Allinson (K)

Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, UK; Department of Pathology, Cambridge University Hospitals NHS Trust, Cambridge, UK.

Catherine E Dawson (CE)

Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, UK.

James B Rowe (JB)

Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, UK; MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK. Electronic address: james.rowe@mrc-cbu.cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH